reports
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Co...
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in a fireside chat at Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024 at 9:20 a.m. The fireside chat will be webcasted and available under “...
Mainz Biomed Presented Industry Leading Results of its Pooled Study at...
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024 New study data confirmed previous ColoFuture and eAArly DETECT study performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia Results from pooled study represents the third consecutive confirmation of the consistently good performance of Mainz Biomed’s mRNA biomarkers to detect CRC and precancerous lesions BERKELEY, Calif. and MAINZ, Germany, June 03, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagno...
Medicenna Reports Significant Survival Benefit in Patients with Recurr...
Medicenna Reports Significant Survival Benefit in Patients with Recurrent Glioblastoma Following Treatment with Bizaxofusp When Compared to a Matched External Control Arm at the 2024 ASCO Annual Meeting Single treatment with bizaxofusp achieved significant survival benefit (mOS of 13.5 vs. 7.2 months, p=0.009) and reduced risk of death by almost half (hazard ratio: 0.54, 95% confidence interval: 0.34-0.83) versus a propensity balanced external control (EC) arm irrespective of IL-4 receptor (IL-4R) expression in unresectable recurrent glioblastoma (rGBM) patients in the Phase 2b Study Biz...
Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for M...
Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies START is a pilot program newly launched jointly by the FDA CDER and CBER divisions to further accelerate the development of novel drug and biological products for rare diseasesDNL126 was selected as one of three CDER-regulated products based on eligibility criteria including the potential for clinical benefit for a rare neurodegenerative disease and the drug sponsor’s ability to advance development tow...
BriaCell Presents Clinical Efficacy Data at ASCO 2024
BriaCell Presents Clinical Efficacy Data at ASCO 2024 Bria-IMT™ PFS compares favorably to PFS of most recent treatment in 48% of Antibody-Drug Conjugate (ADC) resistant patientsTherapy well-tolerated with no Bria-IMT™ related discontinuationsClinical data highlight significant potential of Bria-IMT™ in advanced metastatic breast cancerSuperiority of selected Phase 3 regimen and formulation confirmedOral presentation by Mayo Clinic Professor and Principal Investigator, Saranya Chumsri, MD, on Monday June 3; 11:30 AM-1:00 PM CDT PHILADELPHIA and VANCOUVER, British Columbia, June 03, 2024 (...
Vaisala Oyj:n osakepalkkiojärjestelmän mukainen omien osakkeiden luovu...
Vaisala Oyj:n osakepalkkiojärjestelmän mukainen omien osakkeiden luovutus Vaisala OyjPörssitiedote3.6.2024 klo 15.00 Vaisala Oyj:n osakepalkkiojärjestelmän mukainen omien osakkeiden luovutus Vaisala Oyj on luovuttanut yhteensä 1 750 yhtiön hallussa olevaa Vaisalan A-sarjan osaketta vastikkeetta yhtiön sitouttavaan osakepalkkiojärjestelmään 2022–2026 kuuluville avainhenkilöille osakepalkkiojärjestelmän ehtojen mukaisesti. Osakkeiden luovuttaminen suunnatulla maksuttomalla osakeannilla perustui Vaisalan yhtiökokouksen 26.3.2024 hallitukselle antamaan valtuutukseen. Luovutuksen jälkeen yhti...
Introducing the TimeProvider® XT Extension System for Migrating to a M...
Introducing the TimeProvider® XT Extension System for Migrating to a Modern Synchronization and Timing Systems Architecture Accessory device to Microchip’s TimeProvider 4100 grandmaster scales up to 200 fully redundant T1, E1 or CC synchronization outputs CHANDLER, Ariz., June 03, 2024 (GLOBE NEWSWIRE) -- Critical infrastructure communication networks require highly accurate and resilient synchronization and timing, but over time these systems age out and must be migrated to a more modern architecture. Microchip Technology (Nasdaq: MCHP) today announces the new , a fan-out shelf used wi...
Indaptus Therapeutics Announces New Positive Data from Ongoing Phase 1...
Indaptus Therapeutics Announces New Positive Data from Ongoing Phase 1 Trial of Decoy20 Latest data from first and second cohorts support Company’s 'pulse-prime' approach, demonstrating rapid clearance, broad immune activation, and encouraging safety profile Poster Presented at American Society of Clinical Oncology Annual Meeting NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced updated data from its ongoing Phase 1 clinic...
23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and...
23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting – 23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit, including one confirmed partial response – 23ME-00610 monotherapy continues to demonstrate acceptable safety and tolerability, and achieves the prespecified targets for maximal pharmacology at 1400 mg dosed Q3W – Tumor CD200 is emerging as a potential biomarker associated with 23ME-00610 monotherapy efficacy SOUTH SAN FRANCISCO, Calif., June 03, 2024 (GL...
Tonix Pharmaceuticals Presented New Data on Tonmya™ Suggesting Activit...
Tonix Pharmaceuticals Presented New Data on Tonmya™ Suggesting Activity for Improvement in Fibromyalgia-Associated Depression Severity in an Oral Presentation at ASCP Annual Meeting Tonmya treatment was associated with improvement in depressive symptoms as measured by the Beck Depression Inventory-II In addition, post-hoc analyses showed improvement in depression, anxiety, memory and energy items on the Fibromyalgia Impact Questionnaire-Revised New Drug Application (NDA) submission to the FDA on track for the second half of 2024 CHATHAM, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Tonix Ph...
FOREWARN Partners with Vermont Association of REALTORS®
FOREWARN Partners with Vermont Association of REALTORS® Vermont Association of REALTORS® makes FOREWARN services available for its 1,800+ real estate professional members to promote proactive agent safety BOCA RATON, Fla., June 03, 2024 (GLOBE NEWSWIRE) -- FOREWARN, LLC, a red violet company (NASDAQ: RDVT) and the leading provider of real-time information solutions for real estate agents, today announced that Vermont Association of REALTORS® (“VAR”) will offer FOREWARN® services to its 1,800+ members it serves throughout the State of Vermont to promote proactive real estate agent safety...
Scorpius Holdings and Beyond Imagination Announce Trailblazing Partner...
Scorpius Holdings and Beyond Imagination Announce Trailblazing Partnership to Utilize Autonomous AI-Powered Humanoid Robots for American Biomanufacturing Collaboration aims to enhance biomanufacturing reliability, scalability and efficiency Autonomous humanoids designed to complement human labor and enhance productivity through 24/7 operational capabilities Beyond’s Hive Mind capability allows autonomous humanoids to share and scale biomanufacturing knowledge and improve collective intelligence and operational efficiency DURHAM, N.C., June 03, 2024 (GLOBE NEWSWIRE) -- (NYSE American: ...
Post Holdings Announces Upcoming Executive Leadership Changes at Weeta...
Post Holdings Announces Upcoming Executive Leadership Changes at Weetabix and Refrigerated Retail Businesses ST. LOUIS, June 03, 2024 (GLOBE NEWSWIRE) -- Post Holdings, Inc. (NYSE:POST), a consumer packaged goods holding company, today announced planned executive leadership changes at its Weetabix and Refrigerated Retail businesses. These transitions and internal promotions are part of the company’s ongoing business succession planning. WeetabixSally Abbott, Managing Director, will transition to a strategic advisor role effective Oct. 1, 2024, through her planned retirement on March 31, ...
Core Molding Technologies to Present and Host 1x1 Meetings at the 14t...
Core Molding Technologies to Present and Host 1x1 Meetings at the 14th Annual East Coast IDEAS Conference on June 13, 2024 COLUMBUS, Ohio, June 03, 2024 (GLOBE NEWSWIRE) -- Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding,” “Core” or the “Company”), a leading engineered materials company specializing in molded structural products, principally in building products, industrial and utilities, medium and heavy-duty truck and powersports industries across the United States, Canada and Mexico, today announced that David Duvall, President and CEO, and John Zimmer, EVP and CFO...
4DMT to Participate in Upcoming Investor Conferences
4DMT to Participate in Upcoming Investor Conferences EMERYVILLE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in fireside chats at upcoming investor conferences in June. Members of the management team will also be available for one-on-one meetings. Jefferies Global Healthcare Conference Presentation Date:Thursday, June 6, 2024Presentation ...
Apogee Minerals Announces Appointment of New Director
Apogee Minerals Announces Appointment of New Director Vancouver, British Columbia, June 03, 2024 (GLOBE NEWSWIRE) -- Apogee Minerals Ltd. (“Apogee” or the “Company”) (TSXV: APMI) is pleased to announce the appointment of Mr. Nicholas Coltura as a Director of the Company. Mr. Coltura is a seasoned Investor Relations Manager specializing in the junior resource sector, working with different junior mining companies listed on the TSXV, CSE and OTC public markets. With several years of experience, Mr. Coltura has honed his expertise in communicating important public company information to a d...
Live Oak Bank Announces First Embedded Banking Partnership with Anatom...
Live Oak Bank Announces First Embedded Banking Partnership with Anatomy Financial, Inc. WILMINGTON, N.C., June 03, 2024 (GLOBE NEWSWIRE) -- Live Oak Bank has announced its first embedded banking partnership with Anatomy Financial Inc., an AI-powered financial automation solution for medical, dental, digital health, and healthcare billing companies. Live Oak’s novel approach is the first of its kind, enabling software companies such as Anatomy to directly deliver Live Oak banking products and services to customers. The result is a collaboration where customers will receive best-in-class b...
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to...
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR” Ticker symbol change to take effect on Wednesday, June 5, 2024 SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company will be changing its ticker symbol from “LIFE” to “ATYR.” Effective at the market open on June 5, 2024, the Company’s common stock will trade on the Nasdaq Cap...
Enphase Energy Launches IQ Battery 5P in Canada
Enphase Energy Launches IQ Battery 5P in Canada FREMONT, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ENPH), a global energy technology company and the world's leading supplier of microinverter-based solar and battery systems, announced today that it started shipping its most powerful home battery to-date, the IQ® Battery 5P™, in Canada. The IQ Battery 5P is a modular design with 5 kWh capacity and can be paired with the to provide homeowners reliable electricity to use whenever they need it. The new Enphase® Energy System™ with the IQ Battery 5P enables configurations ranging fr...
FangDD Announces Termination Plan for Its ADR Facility, and the Plan t...
FangDD Announces Termination Plan for Its ADR Facility, and the Plan to Hold an Extraordinary General Meeting of Shareholders SHENZHEN, China, June 03, 2024 (GLOBE NEWSWIRE) -- Fangdd Network Group Ltd. (Nasdaq: DUO) (“FangDD” or the “Company”) today announced that the Company and The Bank of New York Mellon intend to terminate the Deposit Agreement, dated October 31, 2019, among FangDD, The Bank of New York Mellon, as the depositary for the Company’s American depositary shares (the “ADS”), and owners and holders of ADSs. As a result, the Company’s existing American depositary receipts (t...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.